---
title: "CorMedix 公司宣佈 2025 年第三季度初步業績，並上調 2025 年淨收入預期"
description: "‒ 2025 年第三季度未經審計的預計淨收入超過 1.25 億美元"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261879610.md"
published_at: "2025-10-20T12:07:47.000Z"
---

# CorMedix 公司宣佈 2025 年第三季度初步業績，並上調 2025 年淨收入預期

> ‒ 2025 年第三季度未經審計的預計淨收入超過 1.25 億美元

‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ...

### Related Stocks

- [CRMD.US - CorMedix](https://longbridge.com/zh-HK/quote/CRMD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback | CorMedix Inc. (NASDAQ:CRMD) has announced a share repurchase program approved by its board, allowing for up to $75 milli | [Link](https://longbridge.com/zh-HK/news/275654068.md) |
| CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead | CorMedix (NASDAQ:CRMD) announced a strategic shift from a single-product renal company to a diversified specialty pharma | [Link](https://longbridge.com/zh-HK/news/275523726.md) |
| Analyst Expectations For Cormedix's Future | In the past three months, six analysts have rated Cormedix (NASDAQ:CRMD), showing a mix of bullish to bearish sentiments | [Link](https://longbridge.com/zh-HK/news/275609296.md) |
| CorMedix Announces $75 Mln Share Buyback Program | CorMedix Therapeutics (CRMD) has announced a share repurchase program of up to $75 million, approved by its Board, to be | [Link](https://longbridge.com/zh-HK/news/274523823.md) |
| CorMedix Hosts Analyst Day to Showcase Pipeline and Growth Drivers | CorMedix Inc. will host an analyst day on February 10, 2026, in New York, featuring presentations from key opinion leade | [Link](https://longbridge.com/zh-HK/news/274158609.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。